​Effective July 01, 2024, JYNNEOS vaccine has been added to the ADAP formulary.

JYNNEOS is a United States Food and Drug Administration approved vaccine indicated for the prevention of mpox and smallpox infection in adults who are at high risk for either of these infections. In 2022, a global outbreak of mpox occurred that disproportionately impacted gay, bisexual, and other men who have sex with men of which a significant proportion (40 percent) were people with HIV. Although the number of mpox infections has declined substantially since 2022, mpox transmission has persisted in California in 2023 and 2024. The majority of patients with severe illness and death from mpox have been people with HIV and a CD4 cell count less than 200 cells/ml, indicating substantial immunosuppression. Fortunately, JYNNEOS vaccine is effective at preventing most mpox infections and among vaccinated people who still acquire mpox infection, their clinical illness is usually mild. JYNNEOS is a two-dose vaccine that has been demonstrated in clinical trials to be safe and effective for people with HIV. As of June 2024, less than 30 percent of people with HIV in California have received JYNNEOS and CDPH strongly recommends offering JYNNEOS to all patients with HIV per CD​PH Immunization Recommendations for Adults with HIV (PDF), particularly those who are at risk for mpox in accordance with Centers for Disease Control and Prevention's 2024 Adult Immunization Schedules. In addition, patients who have only received one dose of JYNNEOS should still receive their second dose as soon as possible even if the first dose was provided in 2022. See the CDPH website  CDPH mpox Q&A page | Vaccines to learn more about the JYNNEOS vaccine.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary have been updated to reflect the addition of JYNNEOS vaccine.

If you have any questions regarding the addition of this vaccine to the ADAP formulary, please contact the OA Formulary Specialist, James Vo (James.Vo@cdph.ca.gov).

Thank you,